WTA requires genetic sex testing for all women's tour players

The Women’s Tennis Association (WTA) has instituted a mandatory, one‑time genetic test for the SRY gene to determine eligibility for all players on the professional women’s circuit. The screening, which can be performed via cheek swab, saliva or blood sample, took effect on July 21 and mirrors similar policies adopted by World Athletics and the International Olympic Committee.

The test looks for the SRY gene on the Y chromosome, a marker of biological male development. A positive result triggers further medical assessment before a player’s participation is confirmed. The policy has sparked mixed reactions: former world No. 1 Martina Navratilova called it a “step in the right direction,” while former Australian doubles champion Rennae Stubbs questioned the need for the measure, noting there are currently no known transgender women competing in professional tennis. Geneticist Andrew Sinclair, who discovered the SRY gene, has criticized the approach as an oversimplified interpretation of sex biology.